WGS
GeneDx Holdings Corp.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 4 ▼ GeneDx CEO Katherine Stueland sold $455K in open-market shares while…
- Mar 26 ▼ Analysis based on filing metadata only, document content was unavail…
- May 19 to May 20 ▲ 2 days of insider buys: $14.0M by 1 insider, avg $43.12
- May 20 ▲ Two large-position insiders at GeneDx (WGS), Casdin Capital (a direc…
- Jun 1 ▼ 1 insider sell $19.1K at $51.74
- Jun 4 to Jun 5 ▲ 2 days of insider buys: $11.1M by 1 insider, avg $55.55
- Jun 8 ▲ GeneDx Holdings Corp. (WGS) insiders show a mixed cluster: Director/…
- Jun 9 to Jun 16 ▼ 2 days of insider sells: $1.1M by 2 insiders, avg $58.97
- Sep 1 ▼ 1 insider sell $31.2K at $83.84
- Sep 9 to Sep 16 ▼ 2 days of insider sells: $1.8M by 2 insiders, avg $94.14
- Nov 9 ▲ GeneDx reported Q3 2026 revenue of $123.1M (+5% YoY) and adjusted EP…
- Nov 9 ▲ Earnings: WGS Q3 2026 Earnings: EPS $0.28 (+280.4% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $25.1M at an average $47.85. 2 insiders sold $3.0M. Price is 7% above their cost.
- InstitutionsMIXED
Q2 2026: 30 added (1 new), 26 trimmed or exited. Largest new: Jane Street Group $14.0M.
- AnalystsBULLISH
11 of 12 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +8.8% to 6.55M shares. 7.3 days to cover, ≈22.0% of shares.
- TrendDOWNTREND
30% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 7.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Corvex Management LP | ADD | $328.5M |
| GOLDMAN SACHS GROUP INC | ADD | $114.6M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | ADD | $96.2M |
| MORGAN STANLEY | ADD | $67.8M |
| CITADEL ADVISORS LLC | ADD | $59.4M |
| Aberdeen Group plc | ADD | $31.4M |
| BANK OF AMERICA CORP /DE/ | ADD | $23.8M |
| Assenagon Asset Management S.A. | DOUBLED | $20.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +65%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | BTIG MAINTAIN | Buy |
| Oct 1, 2026 | Guggenheim MAINTAIN | Buy |
| Aug 4, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Aug 4, 2026 | BTIG REITERATE | Buy |
| Jun 29, 2026 | Guggenheim MAINTAIN | Buy |
| Jun 23, 2026 | Piper Sandler MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Fuchs Thomas Director Sep 17, 2026 | EXERCISE | 1,146 sh |
Feeley Kevin CHIEF FINANCIAL OFFICER Sep 16, 2026 | SELL | $106.8K |
Feeley Kevin CHIEF FINANCIAL OFFICER Sep 16, 2026 | SELL | $55.2K |
Feeley Kevin CHIEF FINANCIAL OFFICER Sep 16, 2026 | SELL | $5.0K |
Feeley Kevin CHIEF FINANCIAL OFFICER Sep 16, 2026 | EXERCISE | 7,197 sh |
Feeley Kevin CHIEF FINANCIAL OFFICER Sep 16, 2026 | SELL | $144.5K |
Feeley Kevin CHIEF FINANCIAL OFFICER Sep 16, 2026 | SELL | $52.4K |
Stueland Katherine CHIEF EXECUTIVE OFFICER Sep 16, 2026 | EXERCISE | 18,750 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 4 bullish · 3 bearish · 6 neutral- NEUTRAL SC 13G/ANov 13, 2026
ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 2 to Schedule 13G…
Monitor for any future conversion to Schedule 13D, which would indicate activist intent. The increase is consistent with passive fund rebalancing.
- BULLISH 8-KNov 9, 2026
GeneDx reported Q3 2026 revenue of $123.1M (+5% YoY) and adjusted EPS of $0.28, beating the $0.07…
The EPS beat was driven by strong exome/genome volume growth and margin expansion. The slight trim to volume growth guidance for the full year bears watching, but Q4 guidance for $135M revenue and…
- NEUTRAL SC 13GNov 6, 2026
William Blair Investment Management disclosed a 5.2% passive stake in GeneDx Holdings Corp. via a…
Monitor for any future amendments that could indicate a shift from passive to active intent, though the current filing explicitly disclaims control-related purpose.
- BEARISH CLUSTERSep 18, 2026
GeneDx CEO Katherine Stueland and CFO Kevin Feeley sold a combined $366K in open-market sales over…
CEO open-market selling without a disclosed 10b5-1 plan is a modest negative signal. Monitor for additional insider sales or a Form 144 filing that would indicate a larger planned distribution. The…
All WGS filing & press-release reports (13)
- SC 13G/A reportNov 13, 2026
- 8-K reportNov 9, 2026
- SC 13G reportNov 6, 2026
- CLUSTER reportSep 18, 2026
- CLUSTER reportSep 11, 2026
- 144 reportSep 1, 2026
- 8-K reportJun 16, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 8, 2026
- CLUSTER reportMay 20, 2026
- CLUSTER reportMar 26, 2026
- CLUSTER reportMar 4, 2026
- CLUSTER reportMar 4, 2026